AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Follow-Up Questions
¿Quién es el CEO de AIM ImmunoTech Inc?
Mr. Thomas Equels es el President de AIM ImmunoTech Inc, se unió a la empresa desde 2008.
¿Qué tal es el rendimiento del precio de la acción AIM?
El precio actual de AIM es de $2.61, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de AIM ImmunoTech Inc?
AIM ImmunoTech Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de AIM ImmunoTech Inc?
La capitalización bursátil actual de AIM ImmunoTech Inc es $7.0M
¿Es AIM ImmunoTech Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 2 analistas han realizado calificaciones de análisis para AIM ImmunoTech Inc, incluyendo 1 fuerte compra, 3 compra, 1 mantener, 0 venta, y 1 fuerte venta
